The second China Drug Regulatory Science Conference (2017) was held in Beijing from September 14 to 15. 

The theme of the conference is "quality, Safety and Innovation and Development". 

Jiao Hong, deputy director of the State Food and Drug Administration, attended the meeting and delivered a keynote speech. 

In the keynote speech entitled "Scientific Supervision and Reform and Innovation of Medical Devices," Jiao Hong pointed out that scientific decision-making is an important basis for scientific supervision; deepening the reform of the examination and approval system is the inevitable requirement of scientific supervision; strengthening post-listing supervision is an important embodiment of scientific supervision; promoting the disclosure of information is an important means of scientific supervision. 

Jiao Hong stressed that food and drug safety is a major livelihood and public safety issue, and the CPC Central Committee and the State Council attach great importance to it. It emphasizes the need to ensure food and drug safety with "the most stringent standards, the strictest supervision, the harshest punishment and the most serious accountability", which fully reflects the important position of food and drug supervision in the work of the party and the government. 

It further demonstrates the strong determination of the CPC Central Committee and the State Council to ensure the safety of diet and drug use of the people, and is an important guarantee for the supervision and control of food and drugs. 

In recent years, the supervision of medical devices has been continuously strengthened, the reform of the examination and approval system of medical devices has been further promoted, the quality and efficiency of examination and approval have been continuously improved, and the legal system of medical devices has been basically formed. 

The General Administration strives to grasp the key points in supervision, weak points in quality management, and risk points prone to problems, focus on combing high-risk products and key links in the field of medical device production and operation, and formulate risk prevention and control catalogues. take corresponding regulatory measures. 

At the same time, the General Administration continues to increase the intensity of information disclosure, respond to social concerns in a timely manner, strengthen the policy interpretation of major laws and regulations and regulatory measures, constantly expand information release channels, and integrate information release work into the whole process of supervision. 

Jiao Hong said: on July 19, the Central leading Group for comprehensively deepening Reform examined and approved the "opinions on deepening the Reform of the examination and approval system to encourage Innovation in drugs and Medical Devices," which put forward new requirements for further deepening the reform. 

In accordance with the requirements of the reform, the General Administration will continue to encourage R & D and innovation of medical devices to further meet the needs of clinical use. 

Efforts should be made to build a team of high-level inspectors with full-time inspectors as the main body and part-time inspectors as the supplement. 

And will further give full play to the powerful service function of government websites, improve the quality of information release, increase the initiative and timeliness of policy interpretation, and promote the sharing of information resources. 

At this conference, the representatives of pharmaceutical enterprises read out the honesty declaration of 100 enterprises, "be a law-abiding model and create an honest enterprise". 

In the main forum, the relevant responsible persons of the State Administration, the Health and Family Planning Commission, the Ministry of Human Resources and Social Affairs, the Ministry of Industry and Information Technology, as well as experts and scholars at home and abroad, in view of the current drug regulatory reform measures, pharmaceutical innovation and development of hot and difficult issues were interpreted and discussed. 

At the same time, the conference set up "Food and Drug Regulatory concept and practice Innovation", "Biological products Regulatory system Reform and Industrial Development", "Drug Circulation Regulatory system Reform and promoting the healthy Development of Industry", "Pharmaceutical package and Medicinal excipients Policy Reform and technological Innovation" four special forums. 

Experts and scholars from food and drug regulatory departments, drug production and management enterprises, pharmaceutical colleges and universities, medical institutions, and other topics such as regulatory concept and practical innovation, and the healthy development of the pharmaceutical industry are discussed. 

The conference is sponsored by China Drug Administration Research Association and supported by China Health Media Group. 

Hou Huimin, Ning Guang, Liu Changxiao, Zhang Xingdong, academicians of the Chinese Academy of Engineering, Consumer goods Department of the Ministry of Industry and Information Technology, National Health and Family Planning Science and Education Department, Social Security Research Institute of the Ministry of Human Society, General Office of the General Administration, Medical device Registration Department, Medical device Supervision Department, Inspection Bureau and other departments and bureaus. 

The relevant responsible persons of the State Pharmacopoeia Commission, the examination and Inspection Center, the China Insurance Commission, the Information Center, the Certification Center of licensed pharmacists, the China Health Media Group, the China Food and Drug International Exchange Center, and the China Pharmaceutical Association, and nearly 1300 people attended the meeting, including relevant responsible persons of food and drug regulatory departments in Tianjin, Inner Mongolia, Zhejiang, Hubei, Hunan, Guangdong, Gansu and other provinces (autonomous regions and municipalities).